As important noninvasive method for early NPC screening, the detection of IgA antibodies against latent and lytic Epstein-Barr virus (EBV) proteins in serum has been routinely applied in the high-prevalence areas of NPC [6, 7]. The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.